Carcinoid Tumor  >>  Caprelsa (vandetanib)  >>  Phase N/A
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Caprelsa (vandetanib) / Sanofi
NCT01757470: Vandetanib Risk Minimisation Effectiveness

Completed
N/A
12
Canada
Genzyme, a Sanofi Company
Medullary Thyroid Cancer
02/14
02/14
CaprelsaReg, NCT02109250: CAPRELSA® REGISTRY: a Belgian Registry to Evaluate the Use of Vandetanib (Caprelsa®) in Current Clinical Practice

Completed
N/A
10
Europe
Caprelsa
Genzyme, a Sanofi Company
Metastatic Medullary Thyroid Cancer
06/15
06/15

Download Options